Navigation Links
Preliminary Settlement Agreements Establish $100M Fund for Victims of Tainted Steroids Traced to NECC
Date:12/23/2013

BOSTON, Dec. 23, 2013 /PRNewswire/ -- Owners of the bankrupt New England Compounding Pharmacy ("NECC") and NECC's insurers have reached agreements in principle concerning settlements with Bankruptcy Trustee Paul D. Moore, the Official Unsecured Creditor's Committee (the "Committee") and the Plaintiffs Steering Committee (the "PSC") in multidistrict litigation involving NECC pending in Federal Court in Boston (the "MDL") to contribute an amount estimated to exceed $100 million to a compensation fund to be distributed to NECC creditors, including victims who received injections of tainted steroids traced to NECC.  The settlement agreements are subject to final documentation and Bankruptcy Court approval.

The Center for Disease Control estimates that well over 700 people nation-wide have been diagnosed with fungal meningitis or other serious fungal infections. At least 64 deaths have been confirmed.

Paul Moore, the Trustee of bankrupt NECC, commented, "We are pleased that a significant amount of funds will become available for distribution to victims and their families as compensation for the deaths, injuries and suffering they endured as a result of this tragic meningitis outbreak."

David Molton and William Baldiga, partners at Brown Rudnick and counsel to the Committee, added that these settlements "are a material step in expediting compensation to victims and should bring momentum to the Trustee's and Committee's ongoing and vigorous efforts to add to this victims' fund with settlements from others, including medical care providers and pain clinics that administered the tainted steroids to their patients." 

"This preliminary settlement marks a critical milestone in our efforts to maximize recovery for the victims and their families," added Anne Andrews and Harry Roth, co-chairs of the Committee. "We are enormously pleased with what the Trustee and our Committee have accomplished after prolonged negotiations."

Thomas Sobol, lead counsel for the PSC and the PSC's representative with respect to the negotiations, stated that the PSC is also supportive of the preliminary settlements.

NECC's owners commented that "while they deny any liability or wrongdoing, nonetheless they strongly desire to play a major role in establishing a fund for people who died or suffered as a result of this tragic outbreak."

The victim compensation fund will be funded by cash contributions by the owners of NECC as well as from proceeds from, among other things, insurance, tax refunds and the sale of a related business. Pursuant to the bankruptcy process, Judge Henry J. Boroff of the U.S. Bankruptcy Court of the Eastern District of Massachusetts will be asked to confirm a plan containing the terms of the settlement agreements creating and funding the victim's compensation fund. 

As a reminder to all victims and creditors, the Bankruptcy Court established Wednesday, January 15, 2014, at 4:00pm EST as the deadline for submitting their proofs of claim in the NECC bankruptcy proceeding.  This Bar Date Order establishes procedures for filing and submitting claims for injuries suffered due to NECC's contaminated steroid injections. The Trustee and the Committee stress that it is extremely important that anyone who believes he or she has a claim against NECC or involving an NECC product timely file a proof of claim. Failing to do so may have an impact on a person's ability to obtain a distribution from the compensation fund established to compensate NECC victims or creditors.  Information regarding the filing date deadline and the proof of claim process can be found at  http://www.donlinrecano.com/cases/proofofclaim/necp.  


'/>"/>
SOURCE Brown Rudnick LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Initial Studies of Channel Medsystems Cryothermic Therapy Demonstrate Preliminary Safety and Tolerability; Results Presented at the 42nd AAGL Global Congress
2. Simcere Pharmaceutical Group Reports Preliminary Unaudited Third Quarter 2013 Results
3. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
4. West Completes Preliminary Study Evaluating the SmartDose Electronic Patch Injector Technology Platform, Which Incorporates a Daikyo Crystal Zenith Cartridge
5. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
6. Volcano Corporation Announces Third Quarter 2013 Revenues, Updated Revenue Guidance For Full Year 2013 And Preliminary Revenue Guidance For 2014
7. MEI Pharmas Mitochondrial Inhibitor ME-344 Shows Preliminary Evidence of Single-Agent Activity in First-in-Human Clinical Study
8. Simcere Pharmaceutical Group Reports Preliminary Unaudited Second Quarter 2013 Results
9. Alexza Reports Preliminary 2013 Second Quarter Financial Results
10. Alere Announces Preliminary Results Of Voting At Annual Meeting
11. Hill-Rom Announces Preliminary Fiscal 2013 Third Quarter Results and Search for New CFO; Adjusted Earnings Per Share Expected to be in Line with Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
Breaking Medicine News(10 mins):